계명대학교 의학도서관 Repository

Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry)

Metadata Downloads
Author(s)
Ovidio De FilippoJeehoon KangFrancesco BrunoJung-Kyu HanAndrea SagliettoHan-Mo YangGiuseppe PattiKyung-Woo ParkRadoslaw ParmaHyo-Soo KimLeonardo De LucaHyeon-Cheol GwonMario IannacconeWoo Jung ChunGrzegorz SmolkaSeung-Ho HurEnrico CerratoSeung Hwan HanCarlo di MarioYoung Bin SongJavier EscanedKi Hong ChoiGerard HelftJoon-Hyung DohAlessandra Truffa GiachetSoon-Jun HongSaverio MuscoliChang-Wook NamGuglielmo GalloneDavide CapodannoDaniela TrabattoniYoichi ImoriVeronica DusiBernardo CorteseAntonio MontefuscoFederico ConrottoIacopo ColonnelliImad SheibanGaetano Maria de FerrariBon-Kwon KooFabrizio D'Ascenzo
Keimyung Author(s)
Hur, Seung HoNam, Chang Wook
Department
Dept. of Internal Medicine (내과학)
Journal Title
Am J Cardiol
Issued Date
2021
Volume
156
Abstract
Optimal dual antiplatelet therapy (DAPT) duration for patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcations is an unmet issue. The BIFURCAT registry was obtained by merging two registries on coronary bifurcations. Three groups were compared in a two-by-two fashion: short-term DAPT (≤ 6 months), intermediate-term DAPT (6-12 months) and extended DAPT (>12 months). Major adverse cardiac events (MACE) (a composite of all-cause death, myocardial infarction (MI), target-lesion revascularization and stent thrombosis) were the primary endpoint. Single components of MACE were the secondary endpoints. Events were appraised according to the clinical presentation: chronic coronary syndrome (CCS) versus acute coronary syndrome (ACS). 5537 patients (3231 ACS, 2306 CCS) were included. After a median follow-up of 2.1 years (IQR 0.9-2.2), extended DAPT was associated with a lower incidence of MACE compared with intermediate-term DAPT (2.8% versus 3.4%, adjusted HR 0.23 [0.1-0.54], p <0.001), driven by a reduction of all-cause death in the ACS cohort. In the CCS cohort, an extended DAPT strategy was not associated with a reduced risk of MACE. In conclusion, among real-world patients receiving PCI for coronary bifurcation, an extended DAPT strategy was associated with a reduction of MACE in ACS but not in CCS patients.
Keimyung Author(s)(Kor)
허승호
남창욱
Publisher
School of Medicine (의과대학)
Citation
Ovidio De Filippo et al. (2021). Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). Am J Cardiol, 156, 16–23. doi: 10.1016/j.amjcard.2021.07.005
Type
Article
ISSN
0002-9149
Source
https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0002914921006354
DOI
10.1016/j.amjcard.2021.07.005
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43923
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.